On Wednesday, Feb. 6, Regeneron Pharmaceuticals REGN will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
Regeneron EPS will likely be near $5.72 while revenue will be around $1.71 billion, according to analysts.
In the same quarter last year, Regeneron reported EPS of $5.23 on revenue of $1.58 billion. The analyst consensus estimate would represent a 9.37 percent increase in the company's EPS figure. Revenue would be up 8.09 percent from the year-ago period. The company's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | 5.18 | 4.7 | 4.32 | 4.52 |
| EPS Actual | 5.87 | 5.45 | 4.67 | 5.23 |
Stock Performance
Over the last 52-week period, shares of Regeneron are up 22.29 percent. Over the past 90 days, analysts' have generally adjusted their estimates higher for EPS and revenues. The most common rating from analysts on Regeneron stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Regeneron is scheduled to hold a conference call at 8:30 a.m. ET and it can be accessed here: https://edge.media-server.com/m6/p/3pko57bv
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
